February 2025
PrIMAVeRa proudly took part in the AMR Accelerator Cross-Project Meeting 2025 in Basel, joining representatives from across the AMR Accelerator initiative for insightful discussions and knowledge exchange focused on advancing antimicrobial resistance (AMR) research.
The event featured project updates from:
PrIMAVeRa — presented by Irina Meln
UNITE4TB — Jodie Schildkraut
COMBINE — Igor Stojkov
RespiriTB and RespiriNTM — Meindert H. Lamers
GNA NOW — Kristina Orrling
ERA4TB — Diana Angelica Aguilar Ayala
A highlight of the meeting was a workshop on project sustainability led by Josepine Fernow, Philip Gribbon, and Frederik Deroose from COMBINE. The session sparked thought-provoking conversations on how to ensure that project outcomes remain impactful and continue to drive innovation in AMR research long after the projects conclude.
The AMR Accelerator continues to foster collaboration among its projects, pushing forward vital solutions to tackle the global AMR challenge. PrIMAVeRa remains committed to contributing to this collective mission.
This work has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034420 (PrIMAVeRa). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and
innovation programme and EFPIA. www.imi.europa.eu
This communication reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.